FROM: MarketBeat: Stock Market News and Research Tools
***Akili (AKLI) Stock Forecast & Price Target
Type: Akili Medical Companies S&P 500
***AKLI Consensus Rating Score vs. The Competition
..................................................3.00 ...................................2.71.......................................2.50............
Consensus Rating:.................. BUY.................................MODERATE BUY...................MODERATE BUY
***Predicted Upside..................820.17% Upside..............804.56% Upside....................11.46% Upside
***News Sentiment Rating........Positive News.................Positive News.........................Positive News
About Akili Stock (NASDAQ:AKLI)
Akili, Inc., a digital medicine company, develops cognitive treatments through game-changing technologies. The company provides EndeavorRx, a computer-based testing for cognitive dysfunction across several neurology and psychiatry indications, including attention-deficit hyperactivity disorder, depressive disorder, autism spectrum disorder, multiple sclerosis, and other neuroinflammatory diseases. It also offers selective stimulus management engine mechanism to activate the fronto-parietal cortex area in the brain; body brain trainer for attention, impulsivity, working memory, and goal management; and spatial navigation engine for spatial navigation, memory, and planning and organization. The company was founded in 2011 and is headquartered in Boston, Massachusetts.
